Johnson & Johnson（JNJ）株式概要
ジョンソン・エンド・ジョンソンは、その子会社とともに、ヘルスケア分野における様々な製品の研究開発、製造、販売を世界中で行っている。 詳細
JNJ Community Fair Values
Create NarrativeSee what 882 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Johnson & Johnson 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$273.41 |
| 52週高値 | US$274.90 |
| 52週安値 | US$173.33 |
| ベータ | 0.23 |
| 1ヶ月の変化 | 9.88% |
| 3ヶ月変化 | 17.99% |
| 1年変化 | 52.88% |
| 3年間の変化 | 66.18% |
| 5年間の変化 | 56.92% |
| IPOからの変化 | 43,645.67% |
最新ニュース
Recent updates
Seeking Alpha • Aug 15
Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now
Summary Johnson & Johnson has delivered a 28% total return YTD, outperforming SPY and XLV, but now trades at a premium valuation. Despite solid Q2 results and raised FY 2026 guidance, JNJ's stock is deemed fully priced, warranting a reiterated hold rating. Key risks include MedTech growth softness, ongoing litigation, and macro uncertainties, while Pharma momentum drives guidance upgrades. Technically, JNJ remains in an uptrend, but negative RSI divergence and valuation suggest potential near-term consolidation. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 31
JNJ: New Drug Cycle And Talc Settlement Progress Will Balance Policy Risks
Johnson & Johnson's analyst fair value estimate has been raised from $252.87 to $270.59, reflecting higher Street price targets tied to recent Q2 beats, updated guidance, progress on new medicines, and greater clarity around talc litigation exposure. Analyst Commentary Recent Street research on Johnson & Johnson points to a mix of enthusiasm around execution on new medicines and MedTech, alongside measured caution on policy and competitive pressures.
ナラティブ更新 • Jul 17
JNJ: Oncology Focus And New Medicines Will Drive Confidence Through 2026
Analysts raised the Johnson & Johnson fair value estimate to $305 from $265 after a series of price target increases tied to a recent quarterly beat, higher full year guidance, and growing confidence in the company's new medicines and projected revenue trajectory through 2026. Analyst Commentary Recent Street research around Johnson & Johnson has turned more constructive, with a cluster of upgrades and higher price targets following the latest quarterly results and revised guidance.
ナラティブ更新 • Jul 03
JNJ: Drug Pipeline Optimism Will Face Pressure From Medicare Pricing Rules
For Johnson & Johnson, the analyst price target has been revised higher. The updated fair value estimate has moved from about $181.77 to $212.24 as analysts factor in refreshed revenue growth assumptions, slightly adjusted discount and margin inputs, and a higher future P/E in light of recent research pointing to ongoing new drug momentum and broadly supportive earnings expectations.分析記事 • Jun 21
Johnson & Johnson (JNJ) Stock Could Be 7.3% Undervalued Based On Its Pharma And MedTech Focus
Johnson & Johnson (JNJ) is back in focus after recent share price weakness, with the stock down 2% over the past month and about 3% over the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Johnson & Johnson. Despite the recent share price weakness over the past week and quarter, Johnson & Johnson’s year to date share price return of 10.15% and 1 year total shareholder return of 56.28% point to momentum that has been positive overall. If this kind of move...ナラティブ更新 • Jun 19
JNJ: Future Drug Cycle And Dividend Strength Will Balance Policy And Legal Risks
Analysts have raised the Johnson & Johnson price target to $265 from $252, reflecting increased confidence in the company’s new drug momentum and product cycle, while also considering ongoing policy and partnership risks highlighted in recent research. Analyst Commentary Recent Street research around Johnson & Johnson highlights a mix of enthusiasm about the company’s new drug pipeline and product cycle, alongside fresh policy questions and selected partnership headwinds that investors should factor into expectations for execution and valuation.ナラティブ更新 • Jun 04
JNJ: Future Drug Cycle Momentum Is Expected To Drive Returns
Analysts have nudged their price targets for Johnson & Johnson higher, with recent revisions clustering in the mid to high $260s and up to $280, as they point to strong new drug momentum and product cycle strength as key drivers supporting slightly higher revenue growth expectations and a rich future P/E framework. Analyst Commentary Recent research remains broadly constructive on Johnson & Johnson, with several bullish analysts citing product cycle momentum, new drug contributions, and a supportive P/E setup.ナラティブ更新 • May 14
JNJ: Future Drug Cycle And Legal Outcomes Are Expected To Shape Returns
Analysts have nudged their average price target on Johnson & Johnson slightly higher to about $253, citing stronger momentum from new drugs like Icotyde and Inlexzo, along with increased confidence in the pipeline highlighted in recent research updates. Analyst Commentary Recent research on Johnson & Johnson clusters around the same core themes you are seeing in price target moves, with most commentary tied to execution on new products, confidence in the pipeline, and how the company is positioned within healthcare more broadly.ナラティブ更新 • Apr 24
JNJ: Fair Outlook Balances Healthcare Demand With Legal And Portfolio Reshaping Risks
The analyst price target for Johnson & Johnson has been raised by about $11 to $252.42. Analysts point to stronger modeled revenue growth, higher projected profit margins, and a slightly richer future P/E multiple as key drivers of the update.ナラティブ更新 • Apr 09
JNJ: Fair Outlook Sees Healthcare Demand And Legal Outcomes Shape Resilience
Analysts have made a modest upward adjustment to the fair value estimate for Johnson & Johnson, supported by a series of recent price target increases that reflect their updated views on the product pipeline, medical technology trends, and the broader appeal of healthcare stocks. Analyst Commentary Recent research updates on Johnson & Johnson show a cluster of higher price targets and fresh coverage that investors are watching closely.ナラティブ更新 • Mar 25
JNJ: Fair Outlook Balances Legal Overhang With Core Healthcare Resilience
Analysts lifted the Johnson & Johnson fair value estimate by about $3.79 to $241.08, citing higher assumed revenue growth, slightly adjusted profit margin expectations, and a modestly higher future P/E multiple supported by recent upward price target revisions across the Street. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more constructive, with a series of higher price targets clustered above the latest fair value estimate.新しいナラティブ • Mar 18
Oncology Reliance And MedTech Execution Will Threaten Long Term Earnings Stability
Catalysts About Johnson & Johnson Johnson & Johnson is a global health care company focused on pharmaceuticals and medical technology across Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Mar 11
JNJ: Pharma Pipeline Momentum Balanced By Talc And Orthopedics Uncertainty
Analysts have nudged their average price target on Johnson & Johnson higher by about $5 per share, reflecting updated views on the company’s pharmaceutical pipeline, including stronger expectations around Tremfya and other near term therapies such as Tecvayli, Inlexzo and Darzalex treatment duration. Analyst Commentary Recent Street research on Johnson & Johnson has centered on how the pharma pipeline feeds into valuation, with analysts updating targets around specific products rather than broad macro calls.ナラティブ更新 • Feb 25
JNJ: Oncology Pipeline Sale Plans And Talc Cases Will Shape Future Risk
The analyst price target for Johnson & Johnson has been raised by $1 to $232.50, as analysts factor in slightly higher revenue growth expectations, a modest adjustment to profit margin assumptions, and an updated future P/E of 25.94 following a series of recent target increases and an upgrade from major firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned positive, with several firms lifting price targets and one issuing an upgrade, while a smaller group of voices remains more cautious on how much upside is already reflected in the valuation.ナラティブ更新 • Feb 10
JNJ: Oncology Pipeline And Talc Litigation Will Shape Future Risk Balance
Analysts have lifted their Johnson & Johnson fair value estimate by about US$7 to roughly US$231, reflecting research that points to slightly higher assumed revenue growth, modestly stronger profit margins, and a marginally higher future P/E multiple following a series of recent price target increases and an upgrade from several firms. Analyst Commentary Recent Street research on Johnson & Johnson has leaned more positive, with several firms adjusting price targets higher and one new initiation that frames the shares as a preferred large cap pharmaceutical name.株主還元
| JNJ | US Pharmaceuticals | US 市場 | |
|---|---|---|---|
| 7D | 4.8% | 2.3% | -0.3% |
| 1Y | 52.9% | 53.6% | 19.9% |
業界別リターン: JNJ過去 1 年間で53.6 % のリターンをもたらしたUS Pharmaceuticals業界と一致しました。
リターン対市場: JNJ過去 1 年間で19.9 % の収益を上げたUS市場を上回りました。
価格変動
| JNJ volatility | |
|---|---|
| JNJ Average Weekly Movement | 3.6% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: JNJ 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: JNJの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1886 | 138,200 | Joaquin Duato | www.jnj.com |
ジョンソン・エンド・ジョンソンは、その子会社とともに、ヘルスケア分野における様々な製品の研究開発、製造、販売を世界中で行っている。革新的医療事業とメドテック事業の2つのセグメントで事業を展開している。革新的医療事業では、がん、免疫、神経科学、肺高血圧、感染症、循環器、代謝など様々な治療分野向けの製品を、小売店、卸売業者、販売業者、病院、医療従事者を通じて処方箋使用で販売している。メドテック部門は、外科、整形外科、循環器、視力分野で使用される製品ポートフォリオを卸売業者、病院、小売業者を通じて販売し、専門家分野では医師、看護師、病院、眼科専門家、クリニックで使用されている。また、関節再建、外傷、脊椎、スポーツ関連傷害などをサポートする製品や実現技術、開腹手術、腹腔鏡手術、ロボット手術、器具、エネルギー機器、ステープリングシステム、創傷閉鎖、バイオサージェリー製品、デジタルおよびロボット技術、乳房の美容と再建、ACUVUEブランドのコンタクトレンズ、白内障手術用眼内レンズ、TECNISブランドの白内障および屈折矯正手術に使用されるその他の製品も提供している。同社は1886年に設立され、ニュージャージー州ニューブランズウィックに本社を置いている。
Johnson & Johnson 基礎のまとめ
| JNJ 基礎統計学 | |
|---|---|
| 時価総額 | US$653.35b |
| 収益（TTM） | US$21.04b |
| 売上高(TTM) | US$97.93b |
31.3x
PER（株価収益率6.7x
P/SレシオJNJ は割高か？
公正価値と評価分析を参照収益と収入
| JNJ 損益計算書（TTM） | |
|---|---|
| 収益 | US$97.93b |
| 売上原価 | US$31.20b |
| 売上総利益 | US$66.73b |
| その他の費用 | US$45.69b |
| 収益 | US$21.04b |
直近の収益報告
Jun 28, 2026
次回決算日
Oct 13, 2026
| 一株当たり利益（EPS） | 8.73 |
| グロス・マージン | 68.14% |
| 純利益率 | 21.48% |
| 有利子負債／自己資本比率 | 57.7% |
JNJ の長期的なパフォーマンスは？
過去の実績と比較を見る| Johnson & Johnson 配当日 | |
|---|---|
| 配当落ち日 | Aug 25 2026 |
| 配当支払日 | Sep 08 2026 |
| 配当落ちまでの日数 | 5 days |
| 配当支払日までの日数 | 19 days |
JNJ 配当は確実ですか？
JNJ 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/19 21:50 |
| 終値 | 2026/08/19 00:00 |
| 収益 | 2026/06/28 |
| 年間収益 | 2025/12/28 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Johnson & Johnson 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。53
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Matthew Miksic | Barclays |
| Lee Hambright | Bernstein |